Biology is becoming a design discipline. Synthetic biology blends biology, engineering, computer science and biotechnology to create engineered organisms, synthetic DNA and biological circuits for medicine, food, agriculture and industry. Polaris Market Research values the global synthetic biology market at USD 17.96 billion in 2025, with a 2026 estimate of USD 20.95 billion and a forecast of USD 73.62 billion by 2034, a CAGR of 16.97%.

Market Overview

North America held 42.10% of 2025 revenue, helped by strong biotechnology funding, advanced research institutions and active venture capital. Enzymes were the largest product segment at about 31.40%, and PCR was the leading technology. Biotechnology and pharmaceutical companies contributed roughly 46.80% of revenue. Asia Pacific is projected to grow fastest; Invest India reported that the country added over 1,500 biotech startups in 2024, bringing its total to 10,075.

Polaris estimates the contribution of key drivers to growth: AI-assisted protein and pathway design adds roughly 3.2 percentage points, falling DNA synthesis costs 2.8, precision medicine adoption 2.4, precision fermentation 2.1 and biomanufacturing investment 1.8. In June 2026, A*STAR SIFBI and the National University of Singapore launched a joint laboratory to advance innovation and commercialization in the region.

Industry Trends

Precision Medicine and Genetic Engineering

Genetic engineering tools sit at the center of modern therapies. Polaris highlights CRISPR-based therapeutics and genome editing as opportunities for treating genetic disorders, cancer and rare diseases. In February 2026, Weill Cornell Medicine opened a laboratory to speed personalized cell-based cancer therapies. Healthcare was the largest application in 2025.

AI-Assisted Biological Design

Machine learning now supports protein modeling, pathway engineering and genetic circuit design, which reduces the number of laboratory experiments required. Bioinformatics and computer-aided design platforms are expected to be the fastest-growing technology, at a CAGR of 22.40%. In April 2026, Biohub introduced its Virtual Biology Initiative to build a foundational dataset for AI-powered discovery. Falling DNA synthesis costs add further momentum.

Bioengineering Beyond the Clinic

Bioengineering is moving into farms and factories. Engineered crops promise higher yields, disease resistance and better adaptation to climate pressure. Food and agriculture is projected to be the fastest-growing application, helped by precision fermentation, and the EU's 2023 Common Agricultural Policy earmarks about USD 345 billion over five years for sustainable farming. Industrial biotechnology companies are expected to be the fastest-growing end users as sustainable, bio-based manufacturing expands.

Emerging Technologies

Automated biofoundries are in growing deployment, improving throughput. Long-DNA synthesis and cell-free systems are in early commercial use, enabling more complex designs and reducing development constraints, while enzymatic DNA synthesis remains at the pilot stage and could eventually lower costs.

Scale-Up and Biosecurity

Scale-up is the biggest obstacle. Processes that work well in a laboratory can suffer from lower yields, purity problems and higher costs at industrial scale. Biosecurity is rising on the agenda too: in June 2026, Imperial College London launched a Biosecurity Network of Excellence to address emerging threats in an era shaped by AI and biotechnology.

Browse In-depth Market Research Report:

https://www.polarismarketresearch.com/industry-analysis/synthetic-biology-market 

Competitive Landscape

The market is moderately fragmented, with competition across synthetic DNA production, genome engineering, laboratory automation, software platforms and industrial biotechnology. Technology, intellectual property, manufacturing capacity and research partnerships decide who wins, and acquisitions, collaborations and new biomanufacturing facilities remain popular strategies.

Key Players

Companies named in the Polaris report include:

• Thermo Fisher Scientific Inc.
• Danaher Corporation
• GenScript Biotech Corporation
• Twist Bioscience Corporation
• Ginkgo Bioworks Holdings Inc.
• Merck KGaA
• Agilent Technologies Inc.
• Illumina Inc.
• Codexis Inc.
• Novonesis A/S

Conclusion

The synthetic biology market is moving from laboratory promise to commercial reality. Advances in genetic engineering, smarter design software and practical bioengineering are widening its reach across healthcare, agriculture and manufacturing. Challenges around scale-up, regulation and biosecurity remain, but companies that combine strong science, automation and responsible practices should find plenty of room to grow. North America leads today, while Asia Pacific is expected to be the fastest-growing region.

More Trending Latest Reports By Polaris Market Research:

Sonar Systems Market Opportunities

Confidential Computing Market Trends

Chiplets Market Size

Glass Substrate Market Share

Solid State Transformers Market Growth

Beta Carotene Market Forecast

Pea Protein Market Analysis

Software Defined Data Center Market Opportunities

LEO Satellite Market Trends